RxDoctor Payments DataLook up a doctor →

Christopher Lucasti, DO

Infectious Disease · Somers Point, NJNPI 1467447417

Payments from drug & device makers

$2,802,496in general payments, 2019–2025

Across 1,440 payments — averaging $1946.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2.1M
  • Gilead$434K
  • Melinta Therapeutics, LLC$122K
  • AbbVie$116K
  • Merck$25K
  • Janssen Research & Development, LLC$16K
  • plus $19K from 43 others
$1,311in research payments, 2019–2025

Across 8 payments — averaging $163.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$1K

What the payments were for

  • Consulting fees$8,5658%
  • Speaking & faculty fees$64,70758%
  • Travel & lodging$20,35018%
  • Food & beverage$17,91516%
  • Education$2590%
  • Gifts$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,802,496 in reported general payments places this provider in the 95th percentile of 334 infectious disease providers in New Jersey.

See all infectious disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$761,287
Medicare patients
899
Services billed
133,436

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala271$1,183,012
OdefseyEmtricitab/Rilpiviri/Tenof Ala163$596,537
TrogarzoIbalizumab-Uiyk41$470,640
CabenuvaCabotegravir/Rilpivirine41$224,481
ArikayceAmikacin Liposomal/Neb.Accessr13$198,734
TivicayDolutegravir Sodium79$184,750
TriumeqAbacavir/Dolutegravir/Lamivudi47$167,551
DovatoDolutegravir Sodium/Lamivudine50$165,118
PrezcobixDarunavir/Cobicistat64$155,648
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf27$123,560
DelstrigoDoravirine/Lamivu/Tenofov Diso24$77,922
PifeltroDoravirine40$69,600
DescovyEmtricitabine/Tenofov Alafenam30$68,577
GenvoyaElviteg/Cob/Emtri/Tenof Alafen13$49,251
PrezistaDarunavir22$44,503

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya, Truvada$434,499$1,319,746325 claims
Viiv Healthcare CompanyCabenuva, Tivicay, Triumeq, Dovato$6,660$741,900217 claims
Theratechnologies Inc.Trogarzo$1,722$470,64041 claims
Insmed, Inc.Arikayce$548$198,73413 claims
MerckDelstrigo, Pifeltro, Isentress Hd$25,084$184,00188 claims
Johnson & JohnsonPrezcobix, Xarelto$709$163,07377 claims
Janssen Products, LPSymtuza$199$123,56027 claims
Smith+NephewSantyl$446$13,91913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 334 infectious disease providers in New Jersey.

Other infectious disease in Somers Point

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →